Payment overview · 2025
General Payments
$337.15
10 reported records · 5 companies
Healthcare provider profile · identity verified
Scott Jay Wolfe, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NATCHEZ, MS · NPI 1740215797
Verified facts
What the public records show
CMS Open Payments records show Scott Jay Wolfe, M.D. received $337.15 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.51 | 56.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.65 | 20.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.19 | 10.7% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.74 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.06 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $175.00 | 1 |
| Food and Beverage | $162.15 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.65 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 700 | 182 |
| Atorvastatin Calcium | Atorvastatin Calcium | 674 | 192 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 453 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 423 | 133 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 88 |
| Gabapentin | Gabapentin | 302 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 78 |
| Losartan Potassium | Losartan Potassium | 271 | 77 |
| Potassium Chloride | Potassium Chloride | 270 | 80 |
| Furosemide | Furosemide | 246 | 78 |
| Omeprazole | Omeprazole | 211 | 60 |
| Meloxicam | Meloxicam | 207 | 64 |
| Lisinopril | Lisinopril | 203 | 61 |
| Allopurinol | Allopurinol | 193 | 59 |
| Trazodone Hcl | Trazodone Hcl | 192 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 62 |
| Metformin Hcl Er | Metformin Hcl | 162 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 44 |
| Metformin Hcl | Metformin Hcl | 155 | 46 |
| Simvastatin | Simvastatin | 144 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 43 |
| Alprazolam | Alprazolam | 135 | 25 |
| Carvedilol | Carvedilol | 131 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 43 |
| Alendronate Sodium | Alendronate Sodium | 119 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 29 |
| Jardiance | Empagliflozin | 116 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 34 |
| Mirtazapine | Mirtazapine | 104 | 28 |
| Glimepiride | Glimepiride | 101 | 32 |
| Tramadol Hcl | Tramadol Hcl | 101 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 28 |
| Buspirone Hcl | Buspirone Hcl | 99 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 22 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 90 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 90 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 26 |
| Lorazepam | Lorazepam | 79 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 22 |
| Pregabalin | Pregabalin | 77 | 17 |
| Clonazepam | Clonazepam | 76 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 59 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Valsartan | Valsartan | 65 | 17 |
| Levetiracetam | Levetiracetam | 64 | 15 |
| Eliquis | Apixaban | 63 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 11 |
| Farxiga | Dapagliflozin Propanediol | 61 | 11 |
| Montelukast Sodium | Montelukast Sodium | 58 | 16 |
| Fenofibrate | Fenofibrate | 57 | 13 |
| Memantine Hcl | Memantine Hcl | 57 | 11 |
| Baclofen | Baclofen | 56 | 15 |
| Sertraline Hcl | Sertraline Hcl | 56 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 14 |
| Donepezil Hcl | Donepezil Hcl | 51 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 34 |
| Famotidine | Famotidine | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Naproxen | Naproxen | 41 | 15 |
| Spironolactone | Spironolactone | 40 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 14 |
| Ibuprofen | Ibuprofen | 34 | 13 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 28 |
| Valacyclovir | Valacyclovir Hcl | 33 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 22 |
| Linzess | Linaclotide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Prednisone | Prednisone | 24 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Azithromycin | Azithromycin | 14 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $337.15 · 10 records | Amgen Inc. | EVENITY, JARDIANCE, JOURNAVX, MOUNJARO, PROLIA, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error